PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2170546
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2170546
The U.S. Flexible Endoscopic Surgery Robot Market exceeded USD 609.8 million in 2025 and is projected to grow at 11.9% CAGR to reach USD 1.85 billion by 2035. Commercial development increasingly reflects procedure utilization, instrument replenishment, and service relationships within an installed platform base. Cleared bronchoscopy systems provide the established foundation, while urology and gastrointestinal applications broaden development opportunities. Providers assess navigation, imaging, training, and workflow support together. Suppliers must connect equipment placement with practical clinical use and recurring procedural requirements. This makes the quality of implementation and continuing institutional relationships important to revenue development beyond the initial purchase of a robotic platform.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $609.8 Million |
| Forecast Value | $1.85 Billion |
| CAGR | 11.9% |
Lung cancer screening creates a continuing pipeline of peripheral lesions requiring diagnostic assessment, supporting demand for robotic bronchoscopy workflows. High-volume providers seek dependable access, navigation, and confirmation within standardized procedures. Expansion of suitable ambulatory care creates another route to adoption beyond hospital-only purchasing, particularly for compact systems and disposable components. Commercial uptake depends on payment structures that recognize the associated equipment and operating costs. AI-enabled guidance also strengthens demand for integrated planning, image registration, and procedural data. These drivers favor systems that can fit institutional protocols and training, encouraging suppliers to coordinate hardware, software, and clinical support within a useful operating proposition.
Based on category, therapeutic applications generated USD 396.4 million in 2025. Their commercial significance includes recurring instrument use and provider requirements for controlled access during complex endoluminal interventions. Bronchoscopy provides an established platform for demand, while gastrointestinal applications may develop as regulatory and payment conditions permit. Suppliers must support repeat procedures as well as capital placement, connecting instruments and service with the platform's operating role. The segment therefore links equipment procurement with continuing consumption within clinical programs. Commercial performance depends on practical procedural use, making training, navigation, and support relevant to the relationship between an installed system and its contribution to provider workflows.
Within applications, urology is projected to generate USD 647.5 million by 2035. Dedicated robotic ureteroscopy systems could broaden a field in which conventional flexible procedures remain established. Product availability would expand competitive scope beyond bronchoscopy and create new requirements for clinician training and institutional assessment. Adoption depends on procedure economics and evidence of practical workflow benefits in urinary-tract and stone interventions. Suppliers must demonstrate usefulness within the setting where clinicians will operate the equipment. The segment's opportunity therefore rests on matching a dedicated platform with clinical routines and supporting implementation, rather than assume that access to robotics alone will determine procurement and ongoing utilization.
Intuitive Surgical accounted for approximately 58% of U.S. revenue in 2025. Its Ion platform benefits from established commercial resources, hospital relationships, and training infrastructure. As the platform matures, competitive strength increasingly depends on productive use across the installed base. Continuing procedures support instrument demand and reinforce the importance of clinical implementation. The company can draw on its existing institutional relationships to connect equipment placement with training and ongoing support. This positioning reflects the market's movement toward recurring procedural activity, giving operational engagement and platform utilization substantial commercial importance alongside opportunities to place additional systems within provider facilities.
Some of the major players in this market are Johnson and Johnson/Auris Health, Noah Medical, and Avicenna. Established competitors emphasize integrated navigation, imaging, and training, while alternative platforms pursue compact design and disposable instruments. Urology development could create a broader application portfolio for suppliers able to secure access and demonstrate practical advantages. Avicenna's dedicated ureteroscopy offering represents a development pathway whose U.S. participation depends on regulatory clearance. Competitive outcomes increasingly reflect the ability to convert technical capability into durable provider use. Clinical education, procedure economics, deployment complexity, and support for institutional workflows all influence selection. Suppliers must establish an effective operating relationship with providers to sustain adoption beyond initial procedural experience and compete with incumbent installed-base networks.